Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Risberg, Karianne ^a   Fodstad, Øystein ^a   Andersson, Yvonne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 9.2.27 PSEUDOMONAS EXOTOXIN A; ACTIVATING TRANSCRIPTION FACTOR 6; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE INHIBITOR; CATHEPSIN; CATHEPSIN INHIBITOR; ENZYME INHIBITOR; GLUCOSE REGULATED PROTEIN 78; INITIATION FACTOR 2ALPHA; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN BAX; PROTEIN IRE1; PROTEIN MCL 1; PROTEIN PERK; PSEUDOMONAS EXOTOXIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ABT-737; BIPHENYL DERIVATIVE; CALCIUM; IMMUNOTOXIN; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG DOSE SEQUENCE; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; GENE SILENCING; IC 50; MELANOMA; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; RASH; SKIN ULCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; NUDE MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

MUS; PSEUDOMONAS EXOTOXIN;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CALCIUM; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; FEMALE; HUMANS; IMMUNOTOXINS; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; NITROPHENOLS; PIPERAZINES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052531606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024012     Document Type: Article

References (41)

1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, et al. (2006) Cutaneous malignant melanoma. Mayo Clinic proceedings 81: 500-507.
2. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
3. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer research 63: 756-759.
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2011) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine 363: 809-819.
6. Smalley KS, Flaherty KT, (2009) Integrating BRAF/MEK inhibitors into combination therapy for melanoma. British journal of cancer 100: 431-435.
7. Andersson Y, Juell S, Fodstad O, (2004) Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. International journal of cancer 112: 475-483.
8. Natali PG, Giacomini P, Russo C, Steinbach G, Fenoglio C, et al. (1983) Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. Journal of cutaneous pathology 10: 225-237.
9. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, et al. (2004) Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Annals of the New York Academy of Sciences 1028: 340-350.
10. Andersson Y, Engebraaten O, Fodstad O, (2009) Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. British journal of cancer 101: 1307-1315.
11. Risberg K, Fodstad O, Andersson Y, (2009) The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro. International journal of cancer 125: 23-33.
12. Mihic LL, Bulat V, Situm M, Krolo I, Seserko A, (2010) The role of apoptosis in the pathogenesis of malignant melanoma. Collegium antropologicum 34 (Suppl 2): 303-306.
13. Szegezdi E, Macdonald DC, Ni Chonghaile T, Gupta S, Samali A, (2009) Bcl-2 family on guard at the ER. American journal of physiology 296: C941-953.
14. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 435: 677-681.
15. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer cell 10: 389-399.
16. Xu H, Krystal GW, (2010) Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin Cancer Res 16: 4392-4400.
17. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, et al. (2011) Mcl-1 ubiquitionation and destruction. Oncotarget 2: 239-244.
18. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, et al. (2008) In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Sciences of the United States of America 105: 17961-17966.
19. Fodstad O, Kjonniksen I, (1994) Microenvironment revisited: time for reappraisal of some prevailing concepts of cancer metastasis. Journal of cellular biochemistry 56: 23-28.
20. Risberg K, Fodstad O, Andersson Y, (2010) Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells. J Immunother 33: 272-278.
21. Curry BJ, Smith MJ, Hersey P, (1996) Detection and quantitation of melanoma cells in the circulation of patients. Melanoma research 6: 45-54.
22. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer research 59: 2747-2753.
23. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews 58: 621-681.
24. Han Z, Hendrickson EA, Bremner TA, Wyche JH, (1997) A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. The Journal of biological chemistry 272: 13432-13436.
25. Tao W, South VJ, Diehl RE, Davide JP, Sepp-Lorenzino L, et al. (2007) An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Molecular and cellular biology 27: 689-698.
26. Norberg E, Orrenius S, Zhivotovsky B, (2010) Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). Biochemical and biophysical research communications 396: 95-100.
27. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, et al. (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Molecular cell 6: 1099-1108.
28. Straten P, Andersen MH, (2010) The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget 1: 239-245.
29. Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, et al. (2010) ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Molecular cancer therapeutics 9: 2007-2015.
30. Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, et al. (2009) Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Molecular pharmacology 76: 667-678.
31. Xu C, Bailly-Maitre B, Reed JC, (2005) Endoplasmic reticulum stress: cell life and death decisions. The Journal of clinical investigation 115: 2656-2664.
32. Tsai YC, Weissman AM, (2010) The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer. Genes & cancer 1: 764-778.
33. Decuypere JP, Monaco G, Missiaen L, De Smedt H, Parys JB, et al. (2011) IP(3) Receptors, Mitochondria, and Ca Signaling: Implications for Aging. Journal of aging research 2011: 920178.
34. Rong YP, Barr P, Yee VC, Distelhorst CW, (2009) Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. Biochimica et biophysica acta 1793: 971-978.
35. Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, et al. (2005) Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proceedings of the National Academy of Sciences of the United States of America 102: 105-110.
36. Eckenrode EF, Yang J, Velmurugan GV, Foskett JK, White C, (2010) Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling. The Journal of biological chemistry 285: 13678-13684.
37. Distelhorst CW, Bootman MD, (2010) Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: Role in Ca(2+) signaling and disease. Cell calcium.
38. White C, Li C, Yang J, Petrenko NB, Madesh M, et al. (2005) The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nature cell biology 7: 1021-1028.
39. Joseph SK, Hajnoczky G, (2007) IP3 receptors in cell survival and apoptosis: Ca2+ release and beyond. Apoptosis 12: 951-968.
40. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, et al. (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology Baltimore, Md 52: 1310-1321.
41. Yecies D, Carlson NE, Deng J, Letai A, (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115: 3304-3313.